Journal
TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume 35, Issue 4, Pages 286-294Publisher
KARGER
DOI: 10.1159/000141567
Keywords
mesenchymal stromal cells, multipotent; clinical-scale expansion; Good Manufacturing Practice (GMP)
Categories
Funding
- German Federal Ministry of Education and Research [O1GN O531]
- OsteoCord [LSHB-CT-2005-018999]
- European Community
- Austrian Research Foundation (FWF) [NAN200]
- NanoSTEM [NAN202]
Ask authors/readers for more resources
Multipotent mesenchymal stromal cells (MSCs) are currently exploited in numerous clinical trials to investigate their potential in immune regulation, hematopoiesis, and tissue regeneration. The low frequency of MSCs necessitates cell expansion to achieve transplantable numbers. The challenge is to assure safe and high-quality cell production. GMP(Good Manufacturing Practice)-graded cell processing such as cell preparation, culture, and manipulation is mandatory for the progress of such advanced cell therapy. This review summarizes protocols to isolate MSCs from bone marrow and adipose tissue and to expand MSCs for clinical use focussing on culture media composition as well as culture devices and assays to ensure and control quality of the final product.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available